Clorazepic Acid

Summary

Clorazepic Acid (CHEMBL1213252) is an approved small-molecule prodrug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 314.72 Da · C16H11ClN2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1213252
Name	Clorazepic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	2809
ChEBI	CHEBI:3761
Molecular formula	C16H11ClN2O3
Molecular weight	314.72
InChIKey	XDDJGVMJFWAHJX-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O

IUPAC name: 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid

ChEBI definition: A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.

Pharmacological roles (ChEBI): prodrug, anticonvulsant, anxiolytic drug, GABA modulator.

Also known as: ABBOTT-35616 FREE ACID, Chlorazepate, Clorazepate, Clorazepic acid, CLORAZEPATE, CLORAZEPIC ACID

Parent form; salt/anhydrous children: CHEMBL2096631, CHEMBL2106085

Patent coverage: 235 distinct patent families (618 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 586 (95%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).